Drugs / Recombinant Human Mannose-Binding Lectin
Recombinant Human Mannose-Binding Lectin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00886496 | Nov 2006 → Apr 2011 | childhood malignant neoplasm, infectious disease, leukemia, lymphoma +2 | Enzon Pharmaceuticals, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00388999 | Sep 2006 → Feb 2009 | plasma cell myeloma | Enzon Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human mannose-binding lectin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00886496 ↗ |
| Known as | MBL | “Recombinant human mannose-binding lectin (MBL) may be effective in preventing infection” NCT00886496 ↗ |
| Known as | recombinant human MBL | “Patients receive high-dose recombinant human MBL IV over 1 hour” NCT00886496 ↗ |
| Known as | rhMBL | “Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)” NCT00388999 ↗1“Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL)” NCT00886496 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Mannose-Binding Lectin” NCT00388999 ↗ |
| Route | Intravenous | “Patients receive low-dose recombinant human mannose-binding lectin (MBL) IV over 1 hour” NCT00886496 ↗ |